© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Health and Biotech

Top Section/Ad

Top Section/Ad

Most recent


Offer came as markets recovered and volatility fell
Latest block this week in volatile conditions
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
More articles/Ad

More articles/Ad

More articles

  • A Sfr350m block trade in shares of Swiss software company SoftwareOne was priced quickly last night as investors rushed into the first equity capital markets deal in the company's stock since its 2019 IPO.
  • The largest investment banks are not planning on reopening London offices to large numbers of employees any time soon, but they are thinking about how to manage a safe return to work.
  • The UK’s Young & Co’s Brewery, a pub chain, has signed £70m of new loan facilities and has become the latest in a quickly growing list of companies to lean heavily on the Bank of England’s Covid Corporate Financing Facility.
  • ABS
    BMW Bank has released initial price thoughts for its latest car loan securitization, set to test the primary ABS market, which has been dormant for nearly two months.
  • The European Central Bank said this week that it wants to be ‘pragmatic’ with its supervisory review and evaluation process (SREP) this year, keeping Pillar 2 capital requirements at stable levels for banks amid the coronavirus crisis.
  • Synlab’s multi-part liability management exercise has ended up leaning more heavily on the bond market than on loans, with the new FRN leg boosted from €400m to €850m, more than compensating for limited take-up from lenders asked to switch into a longer dated loan. But it should be little surprise that the bond went better, as it paid investors an extra 75bp for a near-identical product.